Has Anil Shrestha, MD received payments from drug or device companies?

Yes. Drug and device makers reported $601,975 in general payments to Anil Shrestha, MD across 1,779 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Anil Shrestha, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Anil Shrestha, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Anil Shrestha, MD

Endocrinology, Diabetes & Metabolism · Jacksonville, FLNPI 1902869837

Payments from drug & device makers

$601,975in general payments, 2019–2025

Across 1,779 payments — averaging $338.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novo Nordisk AS$249K
Eli Lilly$181K
AbbVie$155K
Novo Nordisk$2K
Mannkind Corporation$1K
Sanofi-aventis U.S. LLC$1K
plus $13K from 50 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novo Nordisk AS	812	$248,867
Eli Lilly	7	$181,426
AbbVie	42	$154,748
Novo Nordisk	122	$1,690
Mannkind Corporation	60	$1,370
Sanofi-aventis U.S. LLC	82	$1,334
Dexcom, Inc.	51	$1,092
Insulet Corporation	64	$994
Abbott	66	$974
Amneal Pharmaceuticals LLC	55	$939
Lilly USA, LLC	54	$900
Tosoh Bioscience, Inc.	1	$783
Xeris Pharmaceuticals, Inc.	39	$740
Amgen(2 entities)	41	$740
Boehringer Ingelheim	41	$709
AstraZeneca(2 entities)	39	$660
Radius Health, Inc.	24	$461
Bayer	21	$418
Corcept Therapeutics	14	$374
Medtronic(2 entities)	20	$343
Tandem Diabetes Care, Inc.	12	$205
Amarin Pharma, Inc.	11	$189
IBSA Pharma Inc.	12	$188
Valeritas, Inc.	10	$168
Cequr Corporation	2	$150
Shire North American Group Inc	6	$148
BETA Bionics, Inc.	7	$129
Merck	8	$127
Johnson & Johnson	5	$116
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	6	$111
Sequel Med Tech, LLC	4	$89
Ascensia Diabetes Care US Inc.	4	$83
Astellas Pharma US Inc	4	$81
Ascendis Pharma Endocrinology Inc	3	$69
Lifescan, Inc.	4	$68
Esperion Therapeutics, Inc.	3	$51
Ipsen Biopharmaceuticals, Inc	1	$50
Antares Pharma, Inc.	3	$43
Recordati_rare_diseases_inc.	2	$38
Rhythm Pharmaceuticals, Inc.	1	$27
Tolmar, Inc.	1	$24
Takeda Pharmaceuticals U.S.A., Inc.	1	$22
Novartis	1	$22
Acella Pharmaceuticals, LLC	1	$21
Averitas Pharma Inc.	1	$20
GRT US Holding, Inc.	1	$19
Amryt Pharma Holdings Ltd	1	$19
RGH Enterprises LLC	1	$19
Nevro Corp.	1	$17
Globus Medical	1	$16
Boston Scientific	1	$16
Currax Pharmaceuticals LLC	1	$15
Azurity Pharmaceuticals, Inc.	1	$14
Soleno Therapeutics, Inc.	1	$14
Endo Pharmaceuticals Inc.	1	$13
Clarus Therapeutics Inc.	1	$8

How this compares

$601,975 in reported general payments places this provider in the 90th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.

See all endocrinology, diabetes & metabolism providers in Florida →

Medicare billing

Part B allowed, 2024

$293,445

Medicare patients

1,045

Services billed

4,079

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Jacksonville

David SuttonJacksonville$3.1M
Mae Sheikh AliJacksonville$2.9M
James MageeJacksonville$2.7M
Senan SultanJacksonville$2.5M
J EvansJacksonville$1.7M
Wasim DeebJacksonville$1.5M
Ricardo SilvaJacksonville$867K
Joe ChehadeJacksonville$542K
Firas WardaJacksonville$440K
Khurram WadudJacksonville$338K

See the full list for Florida →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →